FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to neurology, and concerns treating the nervous system, particularly lateral amyotrophic sclerosis. That is ensured by introducing recombinant glutamate oxaloacetate transaminase with oxaloacetate introduction background. Recombinant glutamate oxaloacetate transaminase is administered on the first day in dose of 4.38 units/kg, in the following days - in dose of 1.14 units/kg. Oxaloacetate is orally administered in dose of 100 mg a day. Drugs administration is performed till therapeutic effect is achieved.
EFFECT: such treatment regimen, including administration of glutamate oxaloacetate transaminase in low maintenance doses, provides effective treatment of amyotrophic lateral sclerosis with reduced side effects.
5 cl, 1 dwg, 3 ex, 3 tbl
Title | Year | Author | Number |
---|---|---|---|
TREATMENT METHOD FOR AMYOTROPHIC LATERAL SCLEROSIS | 2023 |
|
RU2804196C1 |
PHARMACEUTICAL COMPOSITION AND METHOD OF THERAPY OF NEURODEGENERATIVE DISORDERS, INCLUDING AMYOTROPHIC LATERAL SCLEROSIS | 2012 |
|
RU2491097C1 |
PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOPHAGY OF MOTOR NEURONS AND USE THEREOF | 2012 |
|
RU2585372C1 |
PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF NEUROLOGIC DISEASES | 2007 |
|
RU2335296C1 |
STRAIN-PRODUCER OF HUMAN GLUTAMATE OXALOACETATE TRANSAMINASE | 2018 |
|
RU2703169C1 |
USE OF SULPHATE SALTS OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1N-BENZO[D]IMIDAZOL-2-AMINE AND THEIR SOLVATES FOR TREATMENT OF MOTOR NEURON DISEASES AND NEUROMUSCULAR DISEASES | 2021 |
|
RU2814327C1 |
THERAPEUTIC AGENT FOR TREATING PATHOLOGICAL SYNDROME AND METHOD OF TREATING MULTIPLE SCLEROSIS | 2011 |
|
RU2519196C2 |
DRUG FOR TREATING MULTIPLE SCLEROSIS AND METHOD OF TREATING MULTIPLE SCLEROSIS | 2010 |
|
RU2509573C2 |
DRUG PREPARATION FOR TREATING INFECTIOUS DISEASES ACCOMPANIED BY NEUROTOXIC DISORDERS, AND METHOD OF TREATING INFECTIOUS DISEASES ACCOMPANIED BY NEUROTOXIC DISORDERS | 2010 |
|
RU2446821C2 |
THERAPEUTIC AGENT | 2013 |
|
RU2595809C2 |
Authors
Dates
2020-01-24—Published
2018-07-27—Filed